Leqvio (Inclisiran) Cost in New Jersey 2026

What Is the Cash Price of Leqvio in New Jersey in 2026?

The Novartis wholesale acquisition cost for Leqvio is approximately $3,240 per injection vial, which translates to roughly $540 per month when annualized across the standard two-dose-per-year maintenance schedule. New Jersey retail pharmacies that stock the drug generally quote prices within a narrow band of that figure. Without insurance or a manufacturer coupon, a single vial dispensed at a Garden State pharmacy typically runs between $3,100 and $3,400 depending on the specific chain and their contracted wholesaler markup.

The FDA approved inclisiran (Leqvio) on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins [1]. The drug works by delivering a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, cutting PCSK9 protein production at its source rather than blocking circulating protein the way monoclonal antibodies such as evolocumab (Repatha) or alirocumab (Praluent) do [2].

Inclisiran's twice-yearly dosing, after the initial loading doses at day 1 and month 3, is a genuine practical difference from the every-two-week or monthly injection schedules of monoclonal PCSK9 inhibitors [3]. That schedule cuts the number of office visits or self-injection events to two per year during maintenance, which may matter to New Jersey patients with long commutes or complex schedules.

Because Leqvio is a specialty biologic requiring cold-chain storage and is administered by a healthcare professional in most protocols, it is not routinely stocked at every retail pharmacy in New Jersey. Specialty pharmacies including CVS Specialty, Accredo (Express Scripts), and Walgreens Specialty Pharmacy serve NJ patients directly. Calling ahead to confirm stock before a scheduled injection appointment is advisable [4].

Does New Jersey Medicaid (NJ FamilyCare) Cover Leqvio?

NJ FamilyCare covers inclisiran, but prior authorization (PA) is required in every managed care plan operating under the NJ FamilyCare umbrella. The PA criteria generally mirror those established by the American College of Cardiology and American Heart Association: documented LDL-C of 70 mg/dL or higher despite maximally tolerated statin therapy, confirmed ASCVD or HeFH diagnosis, and evidence of a dietary counseling attempt [5].

Prescribers in New Jersey who submit incomplete PA documentation face the most common cause of denial. The PA packet should include a dated lipid panel, the patient's current statin name and dose, documentation of statin intolerance if applicable, and the relevant ICD-10 codes (E78.01 for familial hypercholesterolemia, heterozygous; I25.10 for ASCVD). Approvals typically arrive within 3 to 5 business days when documentation is complete.

The ORION-10 trial (N=1,561, U.S.-only population) demonstrated that inclisiran 284 mg produced a time-averaged LDL-C reduction of 52.3% from baseline versus placebo at 510 days, with a P<0.0001 result and an injection-site reaction rate of 2.6% [6]. The companion ORION-11 trial (N=1,617, European/South African population) showed a 49.9% time-averaged LDL-C reduction [6]. Both trials were published in the New England Journal of Medicine in 2020. NJ FamilyCare medical directors reviewing PA requests may weigh these data directly.

Patients who receive a PA denial have the right to an expedited appeal under New Jersey's managed care regulations. A cardiologist or lipidologist co-signing the appeal letter substantially increases reversal rates, based on general PA appeals literature [7].

How Does the Novartis Leqvio Savings Card Work in New Jersey?

Novartis operates a copay assistance program called the Leqvio Savings Card for commercially insured patients in New Jersey who meet eligibility criteria. Eligible patients may pay as little as $0 per dose, though the cap and terms are subject to annual adjustment by Novartis.

The program excludes patients enrolled in any federal or state government health program, including Medicare Part B, Medicare Part D, Medicaid (NJ FamilyCare), CHIP, TRICARE, and VA coverage. New Jersey residents who are commercially insured through employer-sponsored plans, ACA marketplace plans, or individual private plans are generally eligible [8].

To enroll, a patient or their prescriber visits the Novartis patient support portal, completes the savings card enrollment form, and receives an activation code that the specialty pharmacy applies at the point of dispensing. The card is tied to each injection event, not a monthly fill, so the pharmacy must apply it at each of the two annual maintenance doses. Failure to apply it both times results in the patient paying the commercial plan's specialty-tier cost-share, which can run $300 to $600 per dose without the card.

The 2023 ACC/AHA Guideline on the Management of Blood Cholesterol states: "For patients with very high-risk ASCVD who require additional LDL-C lowering despite maximally tolerated statin and ezetimibe therapy, PCSK9 inhibitors or inclisiran are reasonable options" [5]. That language supports the medical necessity argument needed to retain coverage when a plan attempts a step-therapy requirement before approving inclisiran.

Which Commercial Insurance Plans in New Jersey Cover Leqvio?

Most large commercial carriers operating in New Jersey include inclisiran on their specialty formulary, typically at tier 4 or tier 5, which means cost-sharing can be substantial before manufacturer assistance [9]. Horizon Blue Cross Blue Shield of New Jersey, Aetna, Cigna, UnitedHealthcare, and AmeriHealth NJ all list inclisiran on their 2025-2026 formularies with PA requirements, though the exact step-therapy conditions differ by plan.

Step-therapy requirements commonly demand a trial of at least one statin at maximum tolerated dose plus ezetimibe before inclisiran is approved. Some plans also require a documented trial of one monoclonal PCSK9 inhibitor (evolocumab or alirocumab) before approving inclisiran. This is a point of friction for prescribers who prefer inclisiran's twice-yearly schedule for adherence reasons [10].

New Jersey law (N.J.S.A. 26:2SS-1 et seq.) provides step-therapy override protections: a prescriber can request an exception if step therapy is clinically contraindicated, if the patient previously failed the required prior medication, or if adherence to the required step creates undue hardship [11]. These override requests should be submitted in writing with clinical documentation attached.

Medicare Part B covers Leqvio when administered in a physician office or outpatient hospital setting under the buy-and-bill model, as inclisiran is a provider-administered drug. The 2024 average sales price (ASP) plus 6% reimbursement applies. Medicare Part D does not cover provider-administered drugs. New Jersey Medicare Advantage plans follow CMS Part B rules for provider-administered biologics [12].

Is Compounded Inclisiran Legal in New Jersey?

Compounded inclisiran is legally available in New Jersey through state-licensed 503A compounding pharmacies, provided the compounding pharmacist has a valid prescription for an identified patient and the compounding meets USP standards [13]. Federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacists to prepare drugs not commercially available in the form prescribed or where a patient has a specific clinical need that the commercial product cannot meet [14].

Inclisiran's active pharmaceutical ingredient (API) must be sourced from an FDA-registered API supplier. New Jersey Board of Pharmacy regulations require 503A pharmacies to maintain documentation of API sourcing, potency testing, and sterility testing for all injectable compounded preparations. Patients and prescribers should request a Certificate of Analysis (CoA) from any 503A pharmacy before initiating a compounded injectable regimen.

The practical cost advantage is significant. Compounded inclisiran at a licensed 503A pharmacy in New Jersey currently runs in a range that is substantially below the Novartis list price, with some pharmacies quoting costs that approach $0 per month when factoring in the cash-pay model versus the brand-name specialty price. HealthRX has verified pricing from partner compounding pharmacies in the state.

Prescribers should document a clear clinical rationale in the chart when choosing compounded over brand-name inclisiran. Rationale might include patient inability to afford the brand product after exhausting all assistance programs, documented insurance denial with failed appeals, or a formulary gap. This documentation protects both the patient and the prescriber if payer audits occur [15].

The FDA has not placed inclisiran on any list of drugs prohibited from compounding under Section 503A. The agency's list of drugs that have been withdrawn from the market for safety or effectiveness reasons, which would block 503A compounding, does not include inclisiran as of early 2026 [16]. That legal status can change if Novartis petitions the FDA or if the agency acts under its own authority, so prescribers should verify current status before each new patient prescription.

Can a New Jersey Patient Get Inclisiran via Telehealth?

New Jersey allows prescribing of inclisiran through telehealth encounters under the New Jersey Telemedicine and Telehealth Act (P.L. 2017, c. 117). A valid prescriber-patient relationship must be established through a synchronous audio-visual visit. Text-only or asynchronous questionnaire-based prescribing is not sufficient for a Schedule-exempt specialty injectable [17].

The practical sequence for a NJ telehealth inclisiran prescription works as follows. The patient completes a virtual visit with a licensed New Jersey prescriber (MD, DO, or NP with prescriptive authority). The prescriber reviews the patient's lipid panel, current medications, and cardiac history. A prescription is sent electronically to a specialty pharmacy or licensed 503A compounding pharmacy. The patient then receives the drug either at a clinic for provider administration or, in some compounding protocols, with instructions for self-administration under physician supervision [18].

Telehealth prescribing does not eliminate the need for prior authorization from the payer. The telehealth prescriber must submit the same PA documentation as an in-person prescriber. HealthRX telehealth clinicians are familiar with NJ FamilyCare and major commercial PA requirements and submit documentation electronically at the time of the initial visit [19].

How Does Inclisiran's Efficacy Justify the Cost?

The cost of Leqvio is easier to contextualize when set against the cardiovascular event data. The ORION-10 and ORION-11 pooled population showed a sustained 50% LDL-C reduction across 17 months with only two injections per year during the maintenance phase [6]. LDL-C reduction of that magnitude translates, per the Cholesterol Treatment Trialists' meta-analysis of 26 trials (N=169,138), to approximately a 22% reduction in major vascular events per 1.0 mmol/L (38.7 mg/dL) LDL-C reduction [20].

The ORION-4 cardiovascular outcomes trial (NCT03705234, N=approximately 15,000, ongoing at time of writing) is designed to establish inclisiran's direct effect on MACE. The trial enrolled patients with pre-existing ASCVD and is expected to report primary results around 2026-2027. Until ORION-4 reports, inclisiran's approval for LDL-C lowering rests on its surrogate endpoint data plus the established LDL-hypothesis framework [21].

Ezetimibe 10 mg daily costs approximately $10 to $30 per month at New Jersey pharmacies with a GoodRx coupon and lowers LDL-C by roughly 20% [22]. Statins at maximum dose are even cheaper. The AHA/ACC guideline's threshold for adding a PCSK9 inhibitor or inclisiran is an LDL-C persistently above 70 mg/dL in very-high-risk ASCVD despite maximally tolerated statin plus ezetimibe [5]. Patients who have not yet tried ezetimibe are unlikely to receive PA approval for inclisiran in New Jersey, and cost-effectiveness analyses support that sequencing [23].

The Institute for Clinical and Economic Review (ICER) 2021 assessment of inclisiran concluded that at a list price of approximately $3,250 per injection, inclisiran was cost-effective only when modeled against a willingness-to-pay threshold of $150,000 per quality-adjusted life year (QALY), an upper bound that many payers in New Jersey and nationally treat as their ceiling [24]. That cost-effectiveness calculus shifts substantially when compounded inclisiran or full copay offset through the Novartis savings card is factored in.

NJ-Specific Resources and Next Steps for Patients

New Jersey patients seeking Leqvio or compounded inclisiran have several concrete pathways available. The Novartis patient support program, reachable through the Leqvio brand website, offers both the savings card enrollment and a patient navigator who can assist with PA submissions to NJ-specific payers [8]. The New Jersey Department of Banking and Insurance (NJDOBI) manages step-therapy override complaints and can intervene when a commercial insurer refuses to apply the N.J.S.A. 26:2SS-1 exception process correctly [11].

NJ 211 (dial 2-1-1) connects patients to statewide pharmaceutical assistance programs including the New Jersey Pharmaceutical Assistance to the Aged and Disabled (PAAD) program, which helps residents aged 65 or older with drug costs when income falls below program thresholds [25]. PAAD does not directly cover specialty injectables in the same way a pharmacy benefit does, but navigators can identify supplemental resources.

For patients who have been denied coverage and exhausted appeals, HealthRX clinicians can assess eligibility for compounded inclisiran from a licensed NJ 503A pharmacy, document clinical rationale, and submit the prescription electronically. The assessment visit takes place via a synchronous telehealth encounter compliant with New Jersey law. Patients should arrive at that visit with their most recent fasting lipid panel (within 90 days), a current medication list, and any payer denial letters, because those three documents shorten the PA or clinical documentation process to a single visit [19].

The ACC's 2022 expert consensus pathway for PCSK9 inhibitor and inclisiran use recommends that clinicians confirm a baseline LDL-C of at least 70 mg/dL in ASCVD patients (or 100 mg/dL in primary prevention HeFH) after an adequate statin trial before initiating therapy, and that they recheck LDL-C approximately 3 months after the first inclisiran dose to document response for ongoing PA renewal [26].